Genuine Biotech takes third shot at IPO as financial pressures mount
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma Key…
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said on Monday that Shanghai Fosun High Technology, a subsidiary of Fosun International (0656.HK), has pledged 198 million shares of the Shanghai-listed…
Shunned by investors, Henlius hangs up on its Hong Kong listing
The Fosun-backed drugmaker’s privatization comes as its stock price has wilted over 60% since its IPO five years ago and it failed to use the listing to raise additional funds…
FAST NEWS: Fosun Pharma hits pause button on share buyback program
The Latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced Monday it hasn't yet implemented a share buyback since announcing a plan on March 27 to buy back its A shares…
Fosun International on cusp of new ‘asset-light’ era with latest sale
The conglomerate is selling its stake in multinational insurer Ageas, extending a slimming exercise touched off by a liquidity crisis in 2022 Key Takeaways: Fosun International’s total debt-to-capitalization ratio stood…
FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
Recent Articles
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK
600196.SHG
FAST NEWS: Fosun Pharma hits pause button on share buyback program
2196.HK
600196.SHG
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK688428.SHG
- Intsig scans global financial markets for cash with Hong Kong IPO
